No strong inducers of cytochrome P (CYP) A or CYPA or strong inhibitors of CYPA or CYPA within  days prior to registration\r\n*Note: Ixazomib is a substrate of CYPA and CYPA
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP ): No strong inducers of cytochrome P (CYP) A or CYPA or strong inhibitors of CYPA or CYPA\r\n* Note: Ixazomib is a substrate of CYPA and CYPA
Patients should not require chronic use of strong CYPA inhibitors or strong CYPA inducers
Patients who are currently receiving drugs that are strong inducers or inhibitors of CYPA are not eligible; strong inducers or inhibitors of CYPA should be avoided from  days prior to enrollment to the end of the study; Note: CYPA inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Receipt of strong CYPA inhibitors or inducers (for treatment phase)
Strong inhibitors and strong inducers of CYPA should not be used concomitantly.
Use of strong CYPA inhibitors or strong inducers within  days prior to the start of study treatment and for the duration of the study
Is receiving treatment with medication(s) that are known to be strong inhibitors or inducers of CYPA/.
Ongoing treatment with CYPA inducers or strong inhibitors.
Taking strong inducers or inhibitors of CYPs for subjects receiving everolimus
Participants receiving any medications or substances that are known to be strong inhibitors of CYPA, CYPD, and CYPA or strong inducers of CYPA are ineligible;
Treatment with strong CYPA/ inhibitors or inducers
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Concurrent use of strong CYPA inhibitors/inducers is prohibited due to drug-drug interactions with palbociclib; moderate CYPA inhibitors/inducers should be used with caution
known strong CYPA inducers
Participant requires treatment with concomitant drugs that are strong inducers of CYPA within  days of start of study drug.
Participant requires treatment with concomitant drugs that are strong inducers of CYPA within  days of starting study drug.
Currently using concomitant medications that are strong inhibitors or inducers of CYPA.
Drug interactions: Concomitant administration of strong CYPA/ inhibitors or inducers is prohibited while on therapy; patients must not have received these medications for a minimum of  days prior to enrollment
Part B only: No concomitant medications that are strong inhibitors or inducers of cytochrome P A (CYPA) or midazolam
Patients receiving CYPA substrates with narrow therapeutic indices, strong CYPA inhibitors, and strong CYPA inducers.
Concomitant use of strong CYPA inhibitors and inducers.
Has treatment with strong cytochrome P A (CYPA) inducers within  days before the first dose of pevonedistat.
Strong CYPA inhibitors or inducers should not be used within  days of day  dosing until the end of study; moderate CYPA inhibitors or inducers should be used with caution
Participants who are receiving strong CYPA inhibitors and inducers.
Current and concurrent use of strong CYPA inhibitors or inducers.
Patients receiving medications that are strong CYPA inhibitors or inducers are ineligible; concomitant use of strong CYPA inhibitors with T-DM should be avoided; consider an alternate medication with no or minimal potential to inhibit CYPA
Patients taking strong CYPA inhibitors or inducers with risk X (avoid combination) according to lexicomp
Received strong CYPA inhibitors or strong CYPA inducers within  days of starting venetoclax
Subjects who are receiving strong CYPA inhibitors or CYPA inducers
Receiving medications that are strong inhibitors or inducers of CYPA (Appendix D).
Currently receiving any known strong inducers or inhibitors of CYPA/ which cannot be discontinued  days prior to starting study drug
No strong inducers of CYPA (see Appendix .) within  weeks prior to first study treatment.
Is currently using (i.e., within -days prior to first dose) drugs that are known strong CYPA/ inhibitors / inducers.
Strong inhibitors or inducers of hepatic microsomal isoenzymes
Patients who are currently receiving treatment with agents that are known strong inducers or inhibitors of cytochrome P A (CYPA)
Any foods/supplements that are strong inhibitors or inducers of CYPA are prohibited at least  days prior to initiation of and during study treatment
Strong inducers of cytochrome P A (CYPA) are not permitted starting day - of cycle 
Concurrent therapy with drugs known to be strong inhibitors of cytochrome P A (CYPA), cytochrome P D (CYPD), and cytochrome P A (CYPA), or strong inducers of CYPA
known to be strong inducers or inhibitors of CYPA/ (for single agent part); known to be moderate to strong inducers or inhibitors of CYPA/ (for combination part)
Strong inducers or inhibitors of CYPA within  weeks before the first dose of study treatment ( weeks for St John?s Wort).
Strong inducers of CYPA
Patients who require medications that are strong CYPA inhibitors or inducers
REGISTRATION TO TREATMENT (STEP ): Patients should not be receiving concomitant strong CYPA inducers or inhibitors =<  days prior to registration
REGISTRATION TO TREATMENT (STEP ): Patients should not be receiving concomitant strong CYPA inducers or inhibitors =<  days prior to registration
Treatment with strong CYPA inhibitors or inducers within  days before the first dose of study drug; strong CYPA inhibitors/inducers are not permitted during the study, including nutraceutical preparations, e.g., grapefruit juice and St Johns wort; patients must have no prior history of amiodarone in the  months prior to the first dose of pevonedistat
Administration of strong CYPC or CYPA inhibitors or inducers =<  days prior to registration
Patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYPA are not eligible; Note: Dexamethasone for CNS tumors or metastases, on a stable dose, is allowed
Treatment with strong inhibitors or inducers of CYPA are prohibited from  days prior to the first dose of tazemetostat to the end of the study
Participants receiving any medications or substances that are strong inhibitors or inducers of CYPA are ineligible\r\n* Strong inhibitors and inducers of UGT/PgP should be used with caution
Patients must not be taking within  days prior to sub-study registration, nor plan to take while on protocol treatment and for  days after the last dose of study treatment, strong CYPA inhibitors and/or strong CYPA inducers; moderate inhibitors or inducers of isoenzyme CYPA should be avoided, but if necessary can be used with caution
Strong inducers of CYPA are prohibited
Patients treated within the last  days prior to randomization and/or concurrent use of drugs known to be strong CYPA inhibitors or inducers (see appendix .)
Concomitant treatment with strong inhibitors or inducers of CYPA and P-glycoprotein
Patients taking strong inducers or inhibitors of cytochrome P A (CYPA) who cannot interrupt therapy from the time the C- consent is signed through  days after the last dose of study therapy.
Treatment with strong CYPA inhibitors or inducers
Seizures Patients who are currently receiving enzyme inducing anti-epileptic drugs that are known strong inducers or inhibitors of CYPA/ (EIAEDs). Patients with a history of seizures and maintained on an anti-epileptic drug that is not a strong inducers or inhibitor of CYPA/ are eligible.
Strong CYPA/ inducers or inhibitors
Known strong inducers or inhibitors of CYPA/,
Concomitant use of CYPA strong inducers and strong inhibitors
Exposure to strong CYPA and/or UGTA inhibitors and strong CYPA inducers within  days of enrollment (Part ) or randomization (Part ).
Concurrent use of any strong inducers or strong inhibitors of CYPA
Patients requiring medications that are strong inducers or strong inhibitors of CYPA
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P CYPA.
The following concomitant medications are not allowed from  days prior to the first dose of study drug and during venetoclax administration: strong CYPA inhibitors including but not limited to fluconazole, ketoconazole, and clarithromycin or strong CYPA inducers included but not limited to rifampin, carbamazepine
Patients on strong cytochrome p family  superfamily A (CYPA) inducers or inhibitors that are unable to be discontinued
Is receiving concomitant therapy with strong CYPA or CYPA inhibitors or inducers
Patient is taking a drug known to be a strong inhibitor or inducers of the isoenzyme cytochrome P, family , subfamily A (CYPA); participants must be off a strong CYPA inhibitors and inducers for at least two weeks prior to starting the study drug
Use of any medication or substances that are strong inhibitors or inducers of CYPA isoenzymes.
Strong inducers or inhibitors of cytochrome P A (CYPA), strong inhibitors of cytochrome P A (CYPA), or CYPA substrates with a narrow therapeutic range within  weeks before the first dose of study treatment ( weeks for St John's Wort)
Patients requiring strong CYPA inducers or inhibitors are excluded
Administration of medications or foods that are strong inhibitors or inducers of CYPA within  weeks of randomization
That are known strong inducers or inhibitors of CYPA.
HIV-positive patients requiring antivirals which are cytochrome P (CYP) interactive with the investigational agents (CYPA/ strong inducers and inhibitors)
Strong inhibitors or inducers of CYPA
Patients who are receiving treatment with strong inducers or inhibitors of cytochrome P A (CYPA) that cannot be discontinued prior to study entry
Currently taking medication that is substantially metabolized by cytochrome P (CYP) A or CYPA or taking medication known to be strong inhibitors or inducers of CYPA
Required treatment with certain strong CYPA inhibitors or inducers.
Treatment with strong inducers or inhibitors of CYPA or strong inhibitors of CYPA, taken within  weeks or not possible to be stopped for at least  weeks before the date of randomisation.
Current use or anticipated requirement for drugs that are known strong CYPA/ inducers.
Patients who are taking medications that are strong inducers or inhibitors of CYPA
Concomitant therapy with strong CYPA inhibitors or inducers
Patients who require strong CYPA inducers at the time of study enrollment are excluded; for patients who can safely discontinue prior strong CYPA inducers, a wash-out period of  effective half-lives is required prior to st dose of ibrutinib
Has taken strong inhibitors or strong inducers of CYPA within  days before the first dose of study drug.
No concurrent strong CYPA inducers or inhibitors.
Requirement for treatment with any of the prohibited medications including strong CYPA inhibitors, strong CYPA inducers, CYPA substrates with a narrow therapeutic index, and medications with strong risk of QT prolongation
Concurrent therapy with drugs known to be strong inhibitors of CYPA, CYPD, and CYPA, or strong inducers of CYPA
Use of strong Cytochrome P A (CYPA) inducers while on study medication
Currently receiving medications known to be strong inducers or inhibitors of CYPA with a narrow therapeutic window. Strong inducers and inhibitors of CYPA with narrow therapeutic ranges must be discontinued at least  days prior to the first administration of study drug.
Subject requiring concomitant use of strong CYPA inhibitors or inducers.
Strong inhibitors and potent inducers of CYPA
Narrow Therapeutic index substrates, strong inhibitors and strong inducers of CYPA
Patients who are concurrently receiving strong inducers/inhibitors of CYPA
Treatment with CYPA inducers within  days before the first dose of MLN
Receiving strong CYPA inhibitors/ inducers.
Treatment with strong CYPA inhibitors or strong CYPA inducers within  weeks or  drug-elimination half-lives, whichever is longer, prior to initiation of treatment
Systemic treatment with strong inhibitors of CYPA, strong inhibitors of CYPA, or strong CYPA inducers, or use of Ginkgo biloba or St. John's wort within  days before the first dose of study treatment
patients receiving therapy with strong CYPA inhibitors and/or inducers and treatments cannot be stopped or changed to a different medication at least  days prior to starting study drug
Strong inhibitors or inducers of CYPA
Medications or supplements that are known to be strong CYPA mechanism-based inhibitors or strong CYPA inducers and/or P-gp inducers within  days or within  times the inhibitor or inducer half-life (whichever is longer) before the first dose of study drug. The use of these agents is not permitted during the study. See a list of prohibited strong CYPA mechanism-based inhibitors or strong CYPA inducers and/or P-gp inducers based on the US FDA Draft DDI Guidance.
Patients on strong CYPA inducers or inhibitors that cannot be discontinued
Treatment with Strong inhibitors or inducers of CYPA within  weeks prior to receiving study drug
Concurrent administration of medications or foods that are strong inhibitors or inducers of CYPA
Patients who are receiving strong CYP inducers or inhibitors are ineligible